US Company Publishes Long-Term Safety Study of Targeted Radiopharmaceutical for Leukemia

Recently, a new American Society of Hematology (ASH) conference abstract has been developed from the long-term safety and tolerability study of Actimab-A combined with CLAG-M intensive salvage chemotherapy, focusing on the recovery of patients with relapsed or refractory acute myeloid leukemia after treatment. This progress extends the research focus from prior antitumor activity to long-term follow-up, supplementing data for continued development of the combination regimen.

Actimab-A is an investigational targeted α therapy developed by Actinium Pharmaceuticals, composed of the antibody lintuzumab conjugated with actinium-225. This abstract involves follow-up of patients in a Phase I study who survived at least three months after treatment, with emphasis on analyzing blood cell count recovery and potential delayed renal and hepatic toxicity, in order to more comprehensively evaluate the safety profile after intensive treatment.

For patients with relapsed or refractory acute myeloid leukemia, disease control is closely related to maintaining opportunities for subsequent treatment. The speed of blood cell recovery and organ tolerability can affect further treatment and allogeneic hematopoietic cell transplantation planning; long-term evaluation around these issues helps to refine the clinical research framework for the combined use of targeted radiopharmaceuticals and chemotherapy.

Currently, the publicly available information remains a research abstract release and is not sufficient to independently judge all safety results. Future work needs to incorporate complete study data to examine factors such as patient selection, follow-up scope, and toxicity evaluation; previously published efficacy data can serve as development background but cannot replace the evidence from this long-term safety study itself.